2017-10-17 Bayer submits its extended half-life hemophilia A compound for marketing authorization in Japan
2017-10-05 Bayer’s NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms
2017-09-15 Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism
